Letter from the Editor EditorProf. Peter van de Kerkhof, Radboud University, the Netherlands ConferenceAAD 2023 11 May, 2023 16:48
AAD 2023 Highlights Podcast Presented ByRobert van den Heuvel, Medicom ConferenceAAD 2023 4 April, 2023 23:46
Delgocitinib shows promise as topical therapy for chronic hand eczema Presented ByDr Robert Bissonnette, Innovaderm Research, Canada TrialPhase 3, DELTA 1 ConferenceAAD 2023 15 May, 2023 10:58
Vitiligo patients maintain re-pigmentation after ruxolitinib cream withdrawal Presented ByProf. John Harris, UMass Chan Medical School, MA, USA ConferenceAAD 2023 15 May, 2023 10:51
Nemolizumab decreases lesions and itch in prurigo nodularis Presented ByProf. Shawn Kwatra , Johns Hopkins University School of Medicine, MD, USA TrialPhase 3, OLYMPIA 2 ConferenceAAD 2023 15 May, 2023 10:40
Lichen planus: a future indication for baricitinib? Presented ByMs Angelina Hwang , Mayo Clinic College of Medicine, AZ, USA TrialPhase 2 ConferenceAAD 15 May, 2023 09:58
As-needed ruxolitinib shows successful long-term symptom control in AD Presented ByDr Andrew Blauvelt, Oregon Medical Research Center, OR, USA TrialPhase 3, TRuE-AD1 and TRuE-AD2 ConferenceAAD 2023 15 May, 2023 11:43
Dupilumab: a viable option for atopic hand and foot eczema Presented ByProf. Eric Simpson, Oregon Health & Science University, OR, USA TrialPhase 3, LIBERTY-AD-HAFT ConferenceAAD 2023 15 May, 2023 11:33
Topical roflumilast beneficial in atopic dermatitis Presented ByProf. Lawrence Eichenfield, University of California San Diego, CA, USA TrialPhase 3, INTEGUMENT-1 and INTEGUMENT-2 ConferenceAAD 2023 15 May, 2023 11:27
IL-22 receptor blocker reduces itch and skin lesions in AD Presented ByProf. Diamant Thaçi, University of Lübeck, Germany TrialPhase 2 ConferenceAAD 2023 15 May, 2023 11:17
Switching to risankizumab successful in IL-17 inhibitor non-responders Presented ByProf. Richard Warren, University of Manchester, UK TrialPhase 3, aIMM study ConferenceAAD 2023 15 May, 2023 11:56
Novel, selective TYK2 inhibitor shows promise for psoriasis Presented ByProf. April Armstrong, Keck School of Medicine of University of California, LA, USA TrialPhase 2 ConferenceAAD 2023 15 May, 2023 11:51
Izokibep shows remarkably high grades of clinical response in HS Presented ByDr Kim Papp, Probity Medical Research, Canada TrialPhase 3 ConferenceAAD 2023 15 May, 2023 12:31
Bimekizumab could be the new up-and-comer for HS treatment Presented ByProf. Alexa Kimball, Harvard Medical School, MA, USA TrialPhase 3, BE HEARD I and BE HEARD II ConferenceAAD 2023 15 May, 2023 12:26
Biologics in psoriasis: can they prevent joint involvement? Presented ByMs Kathleen Miao, Keck School of Medicine of USC, CA, USA ConferenceAAD 2023 15 May, 2023 12:46
JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata Presented ByDr Maryanne Senna, Lahey Hospital and Medical Center, MA, USA TrialPhase 3, THRIVE-AA1 ConferenceAAD 2023 15 May, 2023 12:41
Biomarkers predicting response of different CSU treatments in children Presented ByMr Alex Nguyen, McGill University, Canada ConferenceAAD 2023 15 May, 2023 12:35